Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other financing activities (2018 - 2025)

Historic Other financing activities for Voyager Therapeutics (VYGR) over the last 8 years, with Q2 2025 value amounting to $434000.0.

  • Voyager Therapeutics' Other financing activities fell 3208.14% to $434000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year decrease of 748.72%. This contributed to the annual value of $1.2 million for FY2024, which is 2221.06% up from last year.
  • According to the latest figures from Q2 2025, Voyager Therapeutics' Other financing activities is $434000.0, which was down 3208.14% from $639000.0 recorded in Q2 2024.
  • In the past 5 years, Voyager Therapeutics' Other financing activities registered a high of $639000.0 during Q2 2024, and its lowest value of $313000.0 during Q2 2022.
  • In the last 5 years, Voyager Therapeutics' Other financing activities had a median value of $434000.0 in 2025 and averaged $476800.0.
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 4603.45% in 2022, then skyrocketed by 5287.08% in 2024.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Other financing activities stood at $580000.0 in 2021, then tumbled by 46.03% to $313000.0 in 2022, then skyrocketed by 33.55% to $418000.0 in 2023, then soared by 52.87% to $639000.0 in 2024, then crashed by 32.08% to $434000.0 in 2025.
  • Its Other financing activities was $434000.0 in Q2 2025, compared to $639000.0 in Q2 2024 and $418000.0 in Q2 2023.